![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SM Wade, MK Scribner, HM Dalman, JM Taylor and RR Neubig
Department of Pharmacology, University of Michigan, Ann Arbor 48109- 0632, USA.
Synthetic peptides are important tools for understanding the sites and mechanisms of receptor/G protein interactions. We examined the structural determinants of receptor-fragment peptides for G protein binding and activation. A dimer of peptides from the carboxyl-terminal (i3c) and amino-terminal (i3n) regions of the alpha 2A-adrenergic receptor is most potent in stimulating guanine-nucleotide exchange of any peptides studied. Stimulation of GTPase by i3n is partially blocked by pertussis toxin treatment, whereas stimulation by i3c is not, which is consistent with action of i3c at the amino terminus of Gi. Both peptides inhibit adenylyl cyclase in Chinese hamster ovary cell membranes, but only the i3c effect is consistent with a pure Gi stimulation. We also examined the mechanism and defined a minimal structural subset of i3c required for G protein activation. Residues 361-365 from the receptor were essential for GTPase stimulation, whereas determinants in the region 368-373 modulated that activity. A specific role for arginines is defined beyond just their positive charge. Complex effects of modifications of Thr373 suggest a regulatory or conformational role of that residue in the previously defined constitutive activation of the alpha 2-adrenergic receptor [J. Biol. Chem. 268:16483-16487 (1993)]. Thus, our data plus recent mutagenesis results support a role for hydrophobicity in the i3n region and a positively charged/arginine-rich region approximately 15-20 residues from the sixth transmembrane span in G protein activation. In contrast, the immediate perimembrane region of i3c seems to have largely conformational effects in producing constitutive activation of the receptors.
This article has been cited by other articles:
|
|
 |
|
  J. R. Lane, B. Powney, A. Wise, S. Rees, and G. Milligan G Protein Coupling and Ligand Selectivity of the D2L and D3 Dopamine Receptors J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 319 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Johnston and D. P. Siderovski Receptor-Mediated Activation of Heterotrimeric G-Proteins: Current Structural Insights Mol. Pharmacol., August 1, 2007; 72(2): 219 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nanoff, R. Koppensteiner, Q. Yang, E. Fuerst, H. Ahorn, and M. Freissmuth The Carboxyl Terminus of the G{alpha}-Subunit Is the Latch for Triggered Activation of Heterotrimeric G Proteins Mol. Pharmacol., January 1, 2006; 69(1): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shacham, M. N. Cheifetz, M. Fridkin, A. J. Pawson, R. P. Millar, and Z. Naor Identification of Ser153 in ICL2 of the Gonadotropin-releasing Hormone (GnRH) Receptor as a Phosphorylation-independent Site for Inhibition of Gq Coupling J. Biol. Chem., August 12, 2005; 280(32): 28981 - 28988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. DeGraff, V. V. Gurevich, and J. L. Benovic The Third Intracellular Loop of alpha 2-Adrenergic Receptors Determines Subtype Specificity of Arrestin Interaction J. Biol. Chem., November 1, 2002; 277(45): 43247 - 43252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Ulfers, J. L. McMurry, A. Miller, L. Wang, D. A. Kendall, and D. F. Mierke Cannabinoid receptor-G protein interactions: G{alpha}i1-bound structures of IC3 and a mutant with altered G protein specificity Protein Sci., October 1, 2002; 11(10): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Greasley, F. Fanelli, A. Scheer, L. Abuin, M. Nenniger-Tosato, P. G. DeBenedetti, and S. Cotecchia Mutational and Computational Analysis of the alpha 1b-Adrenergic Receptor. INVOLVEMENT OF BASIC AND HYDROPHOBIC RESIDUES IN RECEPTOR ACTIVATION AND G PROTEIN COUPLING J. Biol. Chem., November 30, 2001; 276(49): 46485 - 46494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. McCulloch, E. M. Lutz, M. S. Johnson, D. N. Robertson, C. J. MacKenzie, P. J. Holland, and R. Mitchell ADP-Ribosylation Factor-Dependent Phospholipase D Activation by VPAC Receptors and a PAC1 Receptor Splice Variant Mol. Pharmacol., June 1, 2001; 59(6): 1523 - 1532. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Wade, W. K. Lim, K.-L. Lan, D. A. Chung, M. Nanamori, and R. R. Neubig Gi Activator Region of alpha 2A-Adrenergic Receptors: Distinct Basic Residues Mediate Gi versus Gs Activation Mol. Pharmacol., November 1, 1999; 56(5): 1005 - 1013. [Abstract] [Full Text]
|
|
|
|
|
|
D. Wang, W. Sadee, and J. M. Quillan Calmodulin Binding to G Protein-coupling Domain of Opioid Receptors J. Biol. Chem., July 30, 1999; 274(31): 22081 - 22088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Prezeau, J. G. Richman, S. W. Edwards, and L. E. Limbird The zeta Isoform of 14-3-3 Proteins Interacts with the Third Intracellular Loop of Different alpha 2-Adrenergic Receptor Subtypes J. Biol. Chem., May 7, 1999; 274(19): 13462 - 13469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kanwal, D. G. Lowe, and G. J. Trachte Intracellular Fragments of the Natriuretic Peptide Receptor-C (NPR-C) Attenuate Dopamine Efflux Endocrinology, March 1, 1999; 140(3): 1118 - 1124. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. N. Abell, D. J. McCormick, and D. L. Segaloff Certain Activating Mutations within Helix 6 of the Human Luteinizing Hormone Receptor May Be Explained by Alterations That Allow Transmembrane Regions to Activate Gs Mol. Endocrinol., December 1, 1998; 12(12): 1857 - 1869. [Abstract] [Full Text]
|
|
|
|
|
|
J. B. Thompson, S. M. Wade, J. K. Harrison, M. N. Salafranca, and R. R. Neubig Cotransfection of Second and Third Intracellular Loop Fragments Inhibit Angiotensin AT1a Receptor Activation of Phospholipase C in HEK-293 Cells J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 216 - 222. [Abstract] [Full Text]
|
|
|
|
|
|
L. B. Kozell and K. A. Neve Constitutive Activity of a Chimeric D2/D1 Dopamine Receptor Mol. Pharmacol., December 1, 1997; 52(6): 1137 - 1149. [Abstract] [Full Text]
|
|
|
|
|
|
D. Ghanekar, E. M. Hadac, E. L. Holicky, and L. J. Miller Differences in Partial Agonist Action at Cholecystokinin Receptors of Mouse and Rat Are Dependent on Parameters Extrinsic to Receptor Structure: Molecular Cloning, Expression and Functional Characterization of the Mouse Type A Cholecystokinin Receptor J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1206 - 1212. [Abstract] [Full Text]
|
|
|
|
|
|
D. Wang, J. M. Quillan, K. Winans, J. L. Lucas, and W. Sadee Single Nucleotide Polymorphisms in the Human {micro} Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding J. Biol. Chem., September 7, 2001; 276(37): 34624 - 34630. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
